<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">18708154</PMID>
      <DateCompleted>
        <Year>2008</Year>
        <Month>12</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">1084-9521</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>19</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2008</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Seminars in cell &amp; developmental biology</Title>
          <ISOAbbreviation>Semin Cell Dev Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>SOCS regulation of the JAK/STAT signalling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>414</StartPage>
          <EndPage>422</EndPage>
          <MedlinePgn>414-22</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semcdb.2008.07.010</ELocationID>
        <Abstract>
          <AbstractText>The suppressor of cytokine signalling (SOCS) proteins were, as their name suggests, first described as inhibitors of cytokine signalling. While their actions clearly now extend to other intracellular pathways, they remain key negative regulators of cytokine and growth factor signalling. In this review we focus on the mechanics of SOCS action and the complexities of the mouse models that have underpinned our current understanding of SOCS biology.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Croker</LastName>
            <ForeName>Ben A</ForeName>
            <Initials>BA</Initials>
            <AffiliationInfo>
              <Affiliation>The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, 3050 Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kiu</LastName>
            <ForeName>Hiu</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nicholson</LastName>
            <ForeName>Sandra E</ForeName>
            <Initials>SE</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA022556</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 CA022556</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 CA022556-31</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA22556-26</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2008</Year>
          <Month>07</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Semin Cell Dev Biol</MedlineTA>
        <NlmUniqueID>9607332</NlmUniqueID>
        <ISSNLinking>1084-9521</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050826">Suppressor of Cytokine Signaling Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050791" MajorTopicYN="N">STAT Transcription Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050826" MajorTopicYN="N">Suppressor of Cytokine Signaling Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2008</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2008</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2008</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2008</Year>
          <Month>8</Month>
          <Day>19</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2008</Year>
          <Month>12</Month>
          <Day>23</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2008</Year>
          <Month>8</Month>
          <Day>19</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">18708154</ArticleId>
        <ArticleId IdType="mid">NIHMS77115</ArticleId>
        <ArticleId IdType="pmc">PMC2597703</ArticleId>
        <ArticleId IdType="doi">10.1016/j.semcdb.2008.07.010</ArticleId>
        <ArticleId IdType="pii">S1084-9521(08)00049-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Nicola NA.  Guidebook to Cytokines and Their Receptors. Oxford University Press Inc.; Oxford, UK: 1994. </Citation>
        </Reference>
        <Reference>
          <Citation>Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921–924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9202126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9202125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997;387:924–929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9202127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. Embo J. 1995;14:2816–2826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC398400</ArticleId>
            <ArticleId IdType="pubmed">7796808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 1997;89:3148–3154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9129017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jo D, Liu D, Yao S, Collins RD, Hawiger J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med. 2005;11:892–898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16007096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woldman I, Varinou L, Ramsauer K, Rapp B, Decker T. The Stat1 binding motif of the interferon-gamma receptor is sufficient to mediate Stat5 activation and its repression by SOCS3. J Biol Chem. 2001;276:45722–45728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11577084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem. 1998;273:35056–35062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9857039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karlsen AE, Ronn SG, Lindberg K, Johannesen J, Galsgaard ED, Pociot F, Nielsen JH, Mandrup-Poulsen T, Nerup J, Billestrup N. Suppressor of cytokine signaling 3 (SOCS-3) protects beta -cells against interleukin-1beta - and interferon-gamma -mediated toxicity. Proc Natl Acad Sci USA. 2001;98:12191–12196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC59790</ArticleId>
            <ArticleId IdType="pubmed">11593036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croker BA, Metcalf D, Robb L, Wei W, Mifsud S, DiRago L, Cluse LA, Sutherland KD, Hartley L, Williams E, Zhang JG, Hilton DJ, Nicola NA, Alexander WS, Roberts AW. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity. 2004;20:153–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14975238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, Robb L, Greenhalgh CJ, Forster I, Clausen BE, Nicola NA, Metcalf D, Hilton DJ, Roberts AW, Alexander WS. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol. 2003;4:540–545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12754505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, Ihle JN, Rutschman R, Murray PJ. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol. 2003;4:546–550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12754506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H, Yoshimura A. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med. 2004;10:739–743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15208705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robb L, Boyle K, Rakar S, Hartley L, Lochland J, Roberts AW, Alexander WS, Metcalf D. Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. Proc Natl Acad Sci USA. 2005;102:16333–16338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1283454</ArticleId>
            <ArticleId IdType="pubmed">16258063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi Y, Carpino N, Cross JC, Torres M, Parganas E, Ihle JN. SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. Embo J. 2003;22:372–384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC140741</ArticleId>
            <ArticleId IdType="pubmed">12554639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, Hirano T, Chien KR, Yoshimura A. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol. 2003;4:551–556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12754507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura A, Kinjyo I, Matsumura Y, Mori H, Mashima R, Harada M, Chien KR, Yasukawa H, Yoshimura A. SOCS3 Is a Physiological Negative Regulator for Granulopoiesis and Granulocyte Colony-stimulating Factor Receptor Signaling. J Biol Chem. 2004;279:6905–6910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14699146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, Hilton DJ. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 1999;98:597–608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10490099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davey GM, Starr R, Cornish AL, Burghardt JT, Alexander WS, Carbone FR, Surh CD, Heath WR. SOCS-1 regulates IL-15-driven homeostatic proliferation of antigen-naive CD8 T cells, limiting their autoimmune potential. J Exp Med. 2005;202:1099–1108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213211</ArticleId>
            <ArticleId IdType="pubmed">16216888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornish AL, Davey GM, Metcalf D, Purton JF, Corbin JE, Greenhalgh CJ, Darwiche R, Wu L, Nicola NA, Godfrey DI, Heath WR, Hilton DJ, Alexander WS, Starr R. Suppressor of cytokine signaling-1 has IFN-gamma-independent actions in T cell homeostasis. J Immunol. 2003;170:878–886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12517953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chong MM, Cornish AL, Darwiche R, Stanley EG, Purton JF, Godfrey DI, Hilton DJ, Starr R, Alexander WS, Kay TW. Suppressor of cytokine signaling-1 is a critical regulator of interleukin-7-dependent CD8+ T cell differentiation. Immunity. 2003;18:475–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12705851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, Ohishi M, Yoshida H, Kubo M, Yoshimura A. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 2002;17:583–591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12433365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, Seki E, Sato S, Takeuchi O, Takeda K, Akira S, Yamanishi K, Kawase I, Nakanishi K, Kishimoto T. SOCS-1 participates in negative regulation of LPS responses. Immunity. 2002;17:677–687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12433373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gingras S, Parganas E, de Pauw A, Ihle JN, Murray PJ. Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling. J Biol Chem. 2004;279:54702–54707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15491990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ, Nicholson SE, Hilton DJ, O'Neill LA, Hertzog PJ. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol. 2006;7:148–155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16415872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marine JC, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H, Pendeville H, Yasukawa H, Sasaki A, Yoshimura A, Ihle JN. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell. 1999;98:617–627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10490101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto A, Seki Y, Kubo M, Ohtsuka S, Suzuki A, Hayashi I, Tsuji K, Nakahata T, Okabe M, Yamada S, Yoshimura A. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol. 1999;19:6396–6407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC84609</ArticleId>
            <ArticleId IdType="pubmed">10454585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S, Chen S, Xu X, Sundstedt A, Paulsson KM, Anderson P, Karlsson S, Sjogren HO, Wang P. Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med. 2000;191:985–994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2193118</ArticleId>
            <ArticleId IdType="pubmed">10727460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, Hilton DJ, Alexander WS. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 2000;405:1069–1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10890450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ransome MI, Goldshmit Y, Bartlett PF, Waters MJ, Turnley AM. Comparative analysis of CNS populations in knockout mice with altered growth hormone responsiveness. Eur J Neurosci. 2004;19:2069–2079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15090034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turnley AM, Faux CH, Rietze RL, Coonan JR, Bartlett PF. Suppressor of cytokine signaling 2 regulates neuronal differentiation by inhibiting growth hormone signaling. Nat Neurosci. 2002;5:1155–1162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12368809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brender C, Columbus R, Metcalf D, Handman E, Starr R, Huntington N, Tarlinton D, Odum N, Nicholson SE, Nicola NA, Hilton DJ, Alexander WS. SOCS5 is expressed in primary B and T lymphoid cells but is dispensable for lymphocyte production and function. Mol Cell Biol. 2004;24:6094–6103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC480873</ArticleId>
            <ArticleId IdType="pubmed">15199163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krebs DL, Uren RT, Metcalf D, Rakar S, Zhang JG, Starr R, De Souza DP, Hanzinikolas K, Eyles J, Connolly LM, Simpson RJ, Nicola NA, Nicholson SE, Baca M, Hilton DJ, Alexander WS. SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol. 2002;22:4567–4578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC133908</ArticleId>
            <ArticleId IdType="pubmed">12052866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banks AS, Li J, McKeag L, Hribal ML, Kashiwada M, Accili D, Rothman PB. Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest. 2005;115:2462–2471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1190369</ArticleId>
            <ArticleId IdType="pubmed">16127460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. Embo J. 1999;18:1309–1320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1171221</ArticleId>
            <ArticleId IdType="pubmed">10064597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, Schreiber RD, Sheehan K, Hilton DJ, Alexander WS, Hertzog PJ. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol. 2006;7:33–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16311601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qing Y, Costa-Pereira AP, Watling D, Stark GR. Role of tyrosine 441 of interferon-gamma receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation. J Biol Chem. 2005;280:1849–1853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15522878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells. 1999;4:339–351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10421843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Souza D, Fabri LJ, Nash A, Hilton DJ, Nicola NA, Baca M. SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry. 2002;41:9229–9236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12119038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waiboci LW, Ahmed CM, Mujtaba MG, Flowers LO, Martin JP, Haider MI, Johnson HM. Both the Suppressor of Cytokine Signaling 1 (SOCS-1) Kinase Inhibitory Region and SOCS-1 Mimetic Bind to JAK2 Autophosphorylation Site: Implications for the Development of a SOCS-1 Antagonist. J Immunol. 2007;178:5058–5068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17404288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flowers LO, Johnson HM, Mujtaba MG, Ellis MR, Haider SM, Subramaniam PS. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function. J Immunol. 2004;172:7510–7518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15187130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, Baca M, Alexander WS, Metcalf D, Hilton DJ, Nicola NA. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. Embo J. 1999;18:375–385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1171132</ArticleId>
            <ArticleId IdType="pubmed">9889194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babon JJ, McManus E, Yao S, DeSouza DP, Willson TA, Nicola NA, Baca M, Nicholson SE, Norton RS. Structure of mouse SOCS3 reveals the structural basis of the extended SH2 domain function and identifies an unstructured insertion that regulates in vivo stability. Mol Cell. 2006;22:205–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16630890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bullock AN, Rodriguez MC, Debreczeni JE, Songyang Z, Knapp S. Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure. 2007;15:1493–1504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2225448</ArticleId>
            <ArticleId IdType="pubmed">17997974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bullock AN, Debreczeni JE, Edwards AM, Sundstrom M, Knapp S. Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci USA. 2006;103:7637–7642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1472497</ArticleId>
            <ArticleId IdType="pubmed">16675548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science. 1986;234:364–368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2876518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci. 1996;21:267–271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8755249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babon JJ, Yao S, DeSouza DP, Harrison CF, Fabri LJ, Liepinsh E, Scrofani SD, Baca M, Norton RS. Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain. Febs J. 2005;272:6120–6130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16302975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D, Nicola NA. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA. 1998;95:114–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC18144</ArticleId>
            <ArticleId IdType="pubmed">9419338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci. 2002;27:235–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12076535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, Kile BJ, Kent SB, Alexander WS, Metcalf D, Hilton DJ, Nicola NA, Baca M. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA. 1999;96:2071–2076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC26738</ArticleId>
            <ArticleId IdType="pubmed">10051596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Sepulveda P, Ilangumaran S, Rottapel R. Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J Biol Chem. 2000;275:14005–14008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10747851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M, Hattori K, Hatakeyama S, Yada M, Morita S, Kitamura T, Kato H, Nakayama K, Yoshimura A. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem. 2001;276:12530–12538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11278610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol. 2001;21:3547–3557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC100276</ArticleId>
            <ArticleId IdType="pubmed">11313480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irandoust MI, Aarts LH, Roovers O, Gits J, Erkeland SJ, Touw IP. Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor. The EMBO journal. 2007;26:2822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1847666</ArticleId>
            <ArticleId IdType="pubmed">17363902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JG, Metcalf D, Rakar S, Asimakis M, Greenhalgh CJ, Willson TA, Starr R, Nicholson SE, Carter W, Alexander WS, Hilton DJ, Nicola NA. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc Natl Acad Sci USA. 2001;98:13261–13265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC60858</ArticleId>
            <ArticleId IdType="pubmed">11606785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyle K, Egan P, Rakar S, Willson TA, Wicks IP, Metcalf D, Hilton DJ, Nicola NA, Alexander WS, Roberts AW, Robb L. The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood. 2007;110:1466–1474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1975836</ArticleId>
            <ArticleId IdType="pubmed">17510322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee C, Raz R, Gimeno R, Gertner R, Wistinghausen B, Takeshita K, DePinho RA, Levy DE. STAT3 Is a Negative Regulator of Granulopoiesis but Is Not Required for G-CSF-Dependent Differentiation. Immunity. 2002;17:63–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickensheets H, Vazquez N, Sheikh F, Gingras S, Murray PJ, Ryan JJ, Donnelly RP. Suppressor of cytokine signaling-1 is an IL-4-inducible gene in macrophages and feedback inhibits IL-4 signaling. Genes Immun. 2007;8:21–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17093501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasaki A, Inagaki-Ohara K, Yoshida T, Yamanaka A, Sasaki M, Yasukawa H, Koromilas AE, Yoshimura A. The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6. J Biol Chem. 2003;278:2432–2436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12459551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haan S, Ferguson P, Sommer U, Hiremath M, McVicar DW, Heinrich PC, Johnston JA, Cacalano NA. Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem. 2003;278:31972–31979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12783885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cacalano NA, Sanden D, Johnston JA. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol. 2001;3:460–465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11331873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohney SJ, Sanden D, Cacalano NA, Yoshimura A, Mui A, Migone TS, Johnston JA. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol. 1999;19:4980–4988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC84319</ArticleId>
            <ArticleId IdType="pubmed">10373548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peraldi P, Filloux C, Emanuelli B, Hilton DJ, Van Obberghen E. Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase. J Biol Chem. 2001;276:24614–24620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11325969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sommer U, Schmid C, Sobota RM, Lehmann U, Stevenson NJ, Johnston JA, Schaper F, Heinrich PC, Haan S. Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation. Contributions of Src- and receptor-tyrosine kinases. J Biol Chem. 2005;280:31478–31488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16000307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavens D, Montoye T, Piessevaux J, Zabeau L, Vandekerckhove J, Gevaert K, Becker W, Eyckerman S, Tavernier J. A complex interaction pattern of CIS and SOCS2 with the leptin receptor. J Cell Sci. 2006;119:2214–2224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16684815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piessevaux J, Lavens D, Montoye T, Wauman J, Catteeuw D, Vandekerckhove J, Belsham D, Peelman F, Tavernier J. Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J Biol Chem. 2006;281:32953–32966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16956890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seki Y, Hayashi K, Matsumoto A, Seki N, Tsukada J, Ransom J, Naka T, Kishimoto T, Yoshimura A, Kubo M. Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci USA. 2002;99:13003–13008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC130576</ArticleId>
            <ArticleId IdType="pubmed">12242343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kario E, Marmor MD, Adamsky K, Citri A, Amit I, Amariglio N, Rechavi G, Yarden Y. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem. 2005;280:7038–7048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15590694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson SE, Metcalf D, Sprigg NS, Columbus R, Walker F, Silva A, Cary D, Willson TA, Zhang JG, Hilton DJ, Alexander WS, Nicola NA. Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci USA. 2005;102:2328–2333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC549009</ArticleId>
            <ArticleId IdType="pubmed">15695332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007;117:2713–2722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1950459</ArticleId>
            <ArticleId IdType="pubmed">17717605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callus BA, Mathey-Prevot B. SOCS36E, a novel Drosophila SOCS protein, suppresses JAK/STAT and EGF-R signalling in the imaginal wing disc. Oncogene. 2002;21:4812–4821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12101419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, Furlanetto RW. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem. 2001;276:25889–25893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11342531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Gronning LM, Anderson PO, Li S, Edvardsen K, Johnston J, Kioussis D, Shepherd PR, Wang P. Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism. J Biol Chem. 2004;279:34107–34114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15123678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krebs DL, Metcalf D, Merson TD, Voss AK, Thomas T, Zhang JG, Rakar S, O'Bryan MK, Willson TA, Viney EM, Mielke LA, Nicola NA, Hilton DJ, Alexander WS. Development of hydrocephalus in mice lacking SOCS7. Proc Natl Acad Sci USA. 2004;101:15446–15451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC524464</ArticleId>
            <ArticleId IdType="pubmed">15494444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matuoka K, Miki H, Takahashi K, Takenawa T. A novel ligand for an SH3 domain of the adaptor protein Nck bears an SH2 domain and nuclear signaling motifs. Biochemical and biophysical research communications. 1997;239:488–492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9344857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kremer BE, Adang LA, Macara IG. Septins regulate actin organization and cell-cycle arrest through nuclear accumulation of NCK mediated by SOCS7. Cell. 2007;130:837–850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2085444</ArticleId>
            <ArticleId IdType="pubmed">17803907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baetz A, Frey M, Heeg K, Dalpke AH. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J Biol Chem. 2004;279:54708–54715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15491991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machado FS, Esper L, Dias A, Madan R, Gu Y, Hildeman D, Serhan CN, Karp CL, Aliberti J. Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. The Journal of experimental medicine. 2008;205:1077–1086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2373840</ArticleId>
            <ArticleId IdType="pubmed">18411340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machado FS, Johndrow JE, Esper L, Dias A, Bafica A, Serhan CN, Aliberti J. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nature medicine. 2006;12:330–334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16415877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AW, Robb L, Rakar S, Hartley L, Cluse L, Nicola NA, Metcalf D, Hilton DJ, Alexander WS. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA. 2001;98:9324–9329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC55419</ArticleId>
            <ArticleId IdType="pubmed">11481489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong PK, Egan PJ, Croker BA, O'Donnell K, Sims NA, Drake S, Kiu H, McManus EJ, Alexander WS, Roberts AW, Wicks IP. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest. 2006;116:1571–1581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1462939</ArticleId>
            <ArticleId IdType="pubmed">16710471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest. 2001;108:1781–1788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC209467</ArticleId>
            <ArticleId IdType="pubmed">11748261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Hooge AS, van De Loo FA, Arntz OJ, van Den Berg WB. Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol. 2000;157:2081–2091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1885768</ArticleId>
            <ArticleId IdType="pubmed">11106580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van de Loo FA, Kuiper S, van Enckevort FH, Arntz OJ, van den Berg WB. Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice. Am J Pathol. 1997;151:177–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1857913</ArticleId>
            <ArticleId IdType="pubmed">9212744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. Journal of Experimental Medicine. 2001;193:471–481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2195913</ArticleId>
            <ArticleId IdType="pubmed">11181699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu BM, Ishida Y, Robinson GW, Pacher-Zavisin M, Yoshimura A, Murphy PM, Hennighausen L. SOCS3 Negatively Regulates the gp130-STAT3 Pathway in Mouse Skin Wound Healing. J Invest Dermatol. 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18185532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa-Pereira AP, Tininini S, Strobl B, Alonzi T, Schlaak JF, Is'harc H, Gesualdo I, Newman SJ, Kerr IM, Poli V. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci USA. 2002;99:8043–8047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC123017</ArticleId>
            <ArticleId IdType="pubmed">12060750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Kasmi KC, Holst J, Coffre M, Mielke L, de Pauw A, Lhocine N, Smith AM, Rutschman R, Kaushal D, Shen Y, Suda T, Donnelly RP, Myers MG, Jr., Alexander W, Vignali DA, Watowich SS, Ernst M, Hilton DJ, Murray PJ. General nature of the STAT3-activated anti-inflammatory response. J Immunol. 2006;177:7880–7888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17114459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams LM, Sarma U, Willets K, Smallie T, Brennan F, Foxwell BM. Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J Biol Chem. 2007;282:6965–6975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17194701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, Hilton DJ. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 1999;98:597–608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10490099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naka T, Tsutsui H, Fujimoto M, Kawazoe Y, Kohzaki H, Morita Y, Nakagawa R, Narazaki M, Adachi K, Yoshimoto T, Nakanishi K, Kishimoto T. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity. 2001;14:535–545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11371356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimoto M, Tsutsui H, Yumikura-Futatsugi S, Ueda H, Xingshou O, Abe T, Kawase I, Nakanishi K, Kishimoto T, Naka T. A regulatory role for suppressor of cytokine signaling-1 in T(h) polarization in vivo. Int Immunol. 2002;14:1343–1350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12407025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daegelmann C, Herberth G, Roder S, Herbarth O, Giese T, Kramer U, Behrendt H, Borte M, Heinrich J, Emmrich F, Lehmann I. Association between suppressors of cytokine signalling, T-helper type 1/ T-helper type 2 balance and allergic sensitization in children. Clin Exp Allergy. 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18167120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harada M, Nakashima K, Hirota T, Shimizu M, Doi S, Fujita K, Shirakawa T, Enomoto T, Yoshikawa M, Moriyama H, Matsumoto K, Saito H, Suzuki Y, Nakamura Y, Tamari M. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am J Respir Cell Mol Biol. 2007;36:491–496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17099141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egwuagu CE, Yu CR, Zhang M, Mahdi RM, Kim SJ, Gery I. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J Immunol. 2002;168:3181–3187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11907070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seki Y, Inoue H, Nagata N, Hayashi K, Fukuyama S, Matsumoto K, Komine O, Hamano S, Himeno K, Inagaki-Ohara K, Cacalano N, O'Garra A, Oshida T, Saito H, Johnston JA, Yoshimura A, Kubo M. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med. 2003;9:1047–1054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12847520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinjyo I, Inoue H, Hamano S, Fukuyama S, Yoshimura T, Koga K, Takaki H, Himeno K, Takaesu G, Kobayashi T, Yoshimura A. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med. 2006;203:1021–1031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118269</ArticleId>
            <ArticleId IdType="pubmed">16606674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O'Shea JJ. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA. 2006;103:8137–8142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1459629</ArticleId>
            <ArticleId IdType="pubmed">16698929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egwuagu CE, Yu CR, Li Z, Nussenblatt RB. SOCS5 mRNA levels in peripheral blood mononuclear cells (PBMC): a potential bio-marker for monitoring response of uveitis patients to Daclizumab therapy. J Autoimmun. 2005;24:39–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15725575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe H, Kubo M, Numata K, Takagi K, Mizuta H, Okada S, Ito T, Matsukawa A. Overexpression of suppressor of cytokine signaling-5 in T cells augments innate immunity during septic peritonitis. J Immunol. 2006;177:8650–8657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17142765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozaki A, Seki Y, Fukushima A, Kubo M. The control of allergic conjunctivitis by suppressor of cytokine signaling (SOCS)3 and SOCS5 in a murine model. J Immunol. 2005;175:5489–5497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16210657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohshima M, Yokoyama A, Ohnishi H, Hamada H, Kohno N, Higaki J, Naka T. Overexpression of suppressor of cytokine signalling-5 augments eosinophilic airway inflammation in mice. Clin Exp Allergy. 2007;37:735–742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17456221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams TE, Hansen JA, Starr R, Nicola NA, Hilton DJ, Billestrup N. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J Biol Chem. 1998;273:1285–1287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9430658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tollet-Egnell P, Flores-Morales A, Stavreus-Evers A, Sahlin L, Norstedt G. Growth hormone regulation of SOCS-2, SOCS-3, and CIS messenger ribonucleic acid expression in the rat. Endocrinology. 1999;140:3693–3704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10433229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ram PA, Waxman DJ. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem. 1999;274:35553–35561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10585430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen JA, Lindberg K, Hilton DJ, Nielsen JH, Billestrup N. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol Endocrinol. 1999;13:1832–1843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10551777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Favre H, Benhamou A, Finidori J, Kelly PA, Edery M. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett. 1999;453:63–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10403376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenhalgh CJ, Metcalf D, Thaus AL, Corbin JE, Uren R, Morgan PO, Fabri LJ, Zhang JG, Martin HM, Willson TA, Billestrup N, Nicola NA, Baca M, Alexander WS, Hilton DJ. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem. 2002;277:40181–40184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12208853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, Hilton DJ, Alexander WS. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 2000;405:1069–1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10890450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmiter RD, Norstedt G, Gelinas RE, Hammer RE, Brinster RL. Metallothionein-human GH fusion genes stimulate growth of mice. Science. 1983;222:809–814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6356363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenhalgh CJ, Rico-Bautista E, Lorentzon M, Thaus AL, Morgan PO, Willson TA, Zervoudakis P, Metcalf D, Street I, Nicola NA, Nash AD, Fabri LJ, Norstedt G, Ohlsson C, Flores-Morales A, Alexander WS, Hilton DJ. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest. 2005;115:397–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC546423</ArticleId>
            <ArticleId IdType="pubmed">15690087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenhalgh CJ, Bertolino P, Asa SL, Metcalf D, Corbin JE, Adams TE, Davey HW, Nicola NA, Hilton DJ, Alexander WS. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b) Mol Endocrinol. 2002;16:1394–1406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12040024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T, Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005;24:6406–6417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16007195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T, Nakao A. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res. 2003;9:5295–5298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14614012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, Osieka R. DNA methylation changes in multiple myeloma. Leukemia. 2004;18:1687–1692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15318245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tischoff I, Hengge UR, Vieth M, Ell C, Stolte M, Weber A, Schmidt WE, Tannapfel A. Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut. 2007;56:1047–1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1955493</ArticleId>
            <ArticleId IdType="pubmed">17376806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA. 2003;100:14133–14138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC283558</ArticleId>
            <ArticleId IdType="pubmed">14617776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe D, Ezoe S, Fujimoto M, Kimura A, Saito Y, Nagai H, Tachibana I, Matsumura I, Tanaka T, Kanegane H, Miyawaki T, Emi M, Kanakura Y, Kawase I, Naka T, Kishimoto T. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol. 2004;126:726–735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15327527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, Gores GJ. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology. 2007;132:384–396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2203612</ArticleId>
            <ArticleId IdType="pubmed">17241887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28:29–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11326271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C, Tannapfel A. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene. 2005;24:6699–6708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16007169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida T, Ogata H, Kamio M, Joo A, Shiraishi H, Tokunaga Y, Sata M, Nagai H, Yoshimura A. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. The Journal of experimental medicine. 2004;199:1701–1707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2212816</ArticleId>
            <ArticleId IdType="pubmed">15197228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 2000;95:3765–3770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10845908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M, Billestrup N, Odum N. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood. 2001;97:1056–1062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11159537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood. 2002;100:2926–2931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12351404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho-Vega JH, Rassidakis GZ, Amin HM, Tsioli P, Spurgers K, Remache YK, Vega F, Goy AH, Gilles F, Medeiros LJ. Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma. Leukemia. 2004;18:1872–1878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15385932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Cervantes F, Barrios M, Colomer D, Heiniger A, Torres A. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica. 2004;89:42–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14754605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, Wasik M, Odum N. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia. 2005;19:209–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15618960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi K, Sakai I, Narumi H, Yasukawa M, Kojima K, Minamoto Y, Fujisaki T, Tanimoto K, Hara M, Numata A, Gondo H, Takahashi M, Fujii N, Masuda K, Fujita S. Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha. Leuk Res. 2005;29:173–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15607366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verdier F, Chretien S, Muller O, Varlet P, Yoshimura A, Gisselbrecht S, Lacombe C, Mayeux P. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein. J Biol Chem. 1998;273:28185–28190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9774439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endo T, Sasaki A, Minoguchi M, Joo A, Yoshimura A. CIS1 interacts with the Y532 of the prolactin receptor and suppresses prolactin-dependent STAT5 activation. Journal of biochemistry. 2003;133:109–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12761205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn SL, Bjornholm M, Bates SH, Chen Z, Seifert M, Myers MG., Jr.  Molecular endocrinology. Vol. 19. Baltimore, Md: 2005. Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3; pp. 925–938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15604114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hortner M, Nielsch U, Mayr LM, Heinrich PC, Haan S. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. European journal of biochemistry / FEBS. 2002;269:2516–2526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12027890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, Silva A, Asimakis M, Farley A, Nash AD, Metcalf D, Hilton DJ, Nicola NA, Baca M. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2- binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA. 2000;97:6493–6498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC18633</ArticleId>
            <ArticleId IdType="pubmed">10829066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hortner M, Nielsch U, Mayr LM, Johnston JA, Heinrich PC, Haan S. Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. J Immunol. 2002;169:1219–1227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12133942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto K, Yamaguchi M, Miyasaka N, Miura O. SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. Biochemical and biophysical research communications. 2003;310:1188–1193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14559241</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
